< Back to previous page
Researcher
Michel Delforge
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Hematology (Division)
Member
From1 Jan 2021 → Today - Stem Cell and Developmental Biology (Division)
Member
From1 Apr 2013 → 31 Dec 2020 - Faculty of Medicine (Faculty)
Member
From1 Oct 2000 → 30 Sep 2002
Projects
1 - 10 of 19
- Ultra-sensitive minimal residual disease assessment by blood-based clonotypic mass spectrometry approach in plasma cell dyscrasias (MASSIAS)From1 Jan 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Optimizing the use of bispecific antibody treatment in Multiple Myeloma by studying the immune microenvironment and cellular mechanisms of drug resistance.From1 Oct 2023 → TodayFunding: FWO Strategic Basic Research Grant
- Ultra-sensitive minimal residual disease assessment by blood-based clonotypic mass spectrometry approach in plasma cell dyscrasias (MASSIAS)From1 Oct 2023 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Development, Validation, and Valorization of a Patient Preference Platform to Inform Healthcare Decision-MakingFrom1 Mar 2023 → TodayFunding: IOF - technology validation in lab
- Positron emission tomography combined with innovative laboratory techniques for improved risk and disease assessment in myeloma.From1 Jan 2021 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Risk prediction and modeling of cancer therapy related cardiotoxicityFrom1 Oct 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Atomic Force Microscopy Enhanced Spectroscopy to Study Strains and Seeding of Amyloids In SituFrom1 May 2020 → TodayFunding: FWO Medium Size Research Infrastructure
- Augmenting THherapeutic Effectiveness through Novel AnalyticsFrom1 Apr 2020 → 31 Dec 2023Funding: VLAIO - Personalised Medicine ICON
- Het KU Leuven Kankerinstituut (LKI): interdisciplinaire samenwerking ter bevordering van kankeronderzoek, kankerbehandeling en –zorg.From1 Jan 2020 → TodayFunding: BOF - research organisations
- Unravelling the mechanisms of drug resistance to proteasome inhibitors to optimize treatment in patients with multiple myeloma.From1 Jul 2019 → 30 Jun 2023Funding: Foundations, funds and other with scientific goal
Publications
1 - 10 of 265
- Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.(2024)
Authors: Michel Delforge
Pages: 194 - 202 - Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.(2024)
Authors: Michel Delforge
Pages: e216 - e227 - Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.(2024)
Authors: Michel Delforge
Pages: 301 - 313 - The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)(2023)
Authors: Michel Delforge
- Effects of Idecabtagene Vicleucel ( Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Triple-Class-Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Who Received at Least 3 Lines of Prior Antimyeloma Regimens in the KarMMa-3 Phase 3 Randomized Controlled Trial(2023)
Authors: Michel Delforge
- Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3(2023)
Authors: Michel Delforge
- Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Analysis of Cytopenias and Infections in Pts from KarMMa-3(2023)
Authors: Michel Delforge
- Effects of Idecabtagene Vicleucel ( Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial(2023)
Authors: Michel Delforge
- Outcomes of Patients with Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from the LocoMMotion plus MoMMent Studies(2023)
Authors: Michel Delforge
- An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma(2023)
Authors: Michel Delforge
Pages: 1864 - 1869
Patents
1 - 2 of 2
- Cell therapy for myelodysplastic syndromes (Inventor)
- CELL THERAPY FOR MYELODYSPLASTIC SYNDROMES (Inventor)